AVBP
ArriVent BioPharma, Inc.
$33.69
+0.02 (+0.06%)
At close · Jul 10
Market Cap
$1.57B
Shares
46,574,928
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$33.69
Open$33.65
Day$32.84–34.00
52W$16.10–35.83
Avg vol 30d673K
Short int7.6M · 16.4% float · 9.1d
Short vol43%
Last earningsMay 11, 2026
DataJan 2024–Jul 2026
Filing10-Q · May 11
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 11, 2026
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+38%
above
Price vs 50-day avg
+10%
above
RSI (14)
58
neutral
MACD trend
Negative
52-week position
89%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+11%
trailing
6-month return
+54%
trailing
YTD return
+67%
this year
Relative strength
+45%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $31 › 200d $24 — 50d above 200d
Institutional flow
Accumulating
6 of 139 funds reported for Jun 30 · net +64.2K sh shares · +3 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
16.37% of float · ▼ -2.8% MoM · 9.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
139 holders — near 2-yr high, broad support
Squeeze score
71
high risk · 0–100
Fundamentals
EPS growth
−69%
Y/Y
Balance sheet
$45.5M
net cash
Quant / Vol
risk profile
Volatility
56%
annualized · 1-yr
Max drawdown
−25%
past year
ATR
4.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+38%
Bullish
Price vs 50-day avg
+10%
Bullish
RSI (14)
58
Neutral
MACD trend
Negative
Bearish
52-week position
89%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $31 › 200d $24 — 50d above 200d
Institutional flow
Accumulating
6 of 139 funds reported for Jun 30 · net +64.2K sh shares · +3 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
16.37% of float · ▼ -2.8% MoM · 9.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
139 holders — near 2-yr high, broad support
Price context
position in its 52-week range
52-wk low $16
Now $34 · 89%
52-wk high $36
vs 200-day avg +38%
vs 50-day avg +10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AVBP
this stock
ArriVent BioPharma, Inc.
|
$1.57B | +67.4% | — | — | 16.4% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.67B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +4.4% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AVBP | -2.8% | +10.5% | +53.8% | -3.0% | +67.5% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -4.2% | +6.4% | +44.8% | -4.1% | +56.7% |